View Older Stories View More Recent Stories

Oct 8, 2018 08:05AM Exelixis (EXEL) Reports Initiation of Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib
Oct 8, 2018 08:00AM Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
Sep 25, 2018 04:05PM Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
Sep 21, 2018 05:54AM Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Sep 21, 2018 01:32AM Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Sep 19, 2018 07:33AM Exelixis (EXEL) Partner Ipsen Reports Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets
Sep 19, 2018 07:32AM Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Sep 19, 2018 07:32AM Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Sep 7, 2018 08:15AM Exelixis (EXEL) Reports New Recommendations for CABOMETYX (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
Sep 7, 2018 08:00AM Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
Sep 5, 2018 04:05PM Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018
Aug 1, 2018 04:05PM Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Jul 17, 2018 04:05PM Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
Jul 5, 2018 06:05AM Exelixis (EXEL) Reports CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Jul 4, 2018 05:00PM Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Jun 27, 2018 08:00AM Exelixis to Be Added to the S&P MidCap 400 Index
Jun 5, 2018 04:05PM Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018
Jun 4, 2018 06:47AM Exelixis (EXEL) Updates Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma
Jun 3, 2018 09:00AM Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
Jun 1, 2018 08:02AM Exelixis (EXEL) Reports Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy
Jun 1, 2018 08:00AM Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metas
May 29, 2018 04:11PM Exelixis (EXEL) Announces U.S. FDA Accepts sNDA for CABOMETYX in Previously Treated Advanced Hepatocellular Carcinoma
May 29, 2018 04:05PM Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
May 22, 2018 04:15PM Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy
May 17, 2018 05:59AM Exelixis (EXEL) Partner Ipsen Reports European Commission Approval of CABOMETYX (Cabozantinib)
May 17, 2018 01:01AM Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
May 10, 2018 05:46AM Exelixis (EXEL) Reports Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib
May 10, 2018 01:01AM Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer
May 8, 2018 04:05PM Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
May 2, 2018 04:06PM Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer
May 2, 2018 04:05PM Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update
Apr 26, 2018 08:00AM Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
Apr 11, 2018 04:05PM Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
Apr 9, 2018 04:07PM Exelixis (EXEL) Announces Election of Dr. Maria Freire to Board
Apr 9, 2018 04:05PM Exelixis Elects Dr. Maria Freire to Its Board of Directors
Mar 28, 2018 05:50AM Exelixis (EXEL) Partner Ipsen Reports EMA Validation of Application for New Indication for CABOMETYX (cabozantinib)
Mar 28, 2018 01:05AM Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Mar 23, 2018 06:04AM Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)
Mar 23, 2018 02:05AM Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Mar 15, 2018 08:02AM Exelixis (EXEL) Submits sNDA for CABOMETYX for Previously Treated Advanced Hepatocellular Carcinoma
Mar 15, 2018 08:00AM Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Mar 6, 2018 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in March
Feb 26, 2018 08:00PM Exelixis Announces Collaborator Daiichi Sankyo’s Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan
Feb 26, 2018 04:05PM Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Feb 14, 2018 04:05PM Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018
Feb 13, 2018 04:10PM Exelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic Radioiodine-Refractory DTC
Feb 13, 2018 04:05PM Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Feb 8, 2018 04:05PM Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018
Feb 7, 2018 08:04AM Exelixis (EXEL) Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory GU Tumors
Feb 7, 2018 08:00AM Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors
View More Recent Stories View Older Stories